Segall Bryant & Hamill LLC Has $60.76 Million Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Segall Bryant & Hamill LLC trimmed its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 25.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 333,444 shares of the medical instruments supplier’s stock after selling 116,778 shares during the quarter. ICU Medical comprises 0.8% of Segall Bryant & Hamill LLC’s portfolio, making the stock its 9th largest holding. Segall Bryant & Hamill LLC owned about 1.37% of ICU Medical worth $60,760,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in shares of ICU Medical by 441.7% in the 2nd quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock worth $691,000 after acquiring an additional 4,744 shares during the period. Sei Investments Co. increased its holdings in shares of ICU Medical by 52.1% in the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock valued at $3,068,000 after buying an additional 9,793 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its stake in shares of ICU Medical by 109.4% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after acquiring an additional 145,485 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of ICU Medical by 0.5% during the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares during the last quarter. Finally, Savant Capital LLC acquired a new position in shares of ICU Medical in the 2nd quarter valued at $431,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,973,261.12. The trade was a 10.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This represents a 16.03 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,502 shares of company stock worth $6,573,496. 6.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on ICUI. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research report on Monday, October 14th. They issued a “hold” rating and a $183.00 price target for the company. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp upped their target price on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Finally, Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.00.

ICU Medical Trading Down 0.2 %

Shares of NASDAQ ICUI opened at $169.70 on Wednesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The stock has a market cap of $4.15 billion, a price-to-earnings ratio of -37.13 and a beta of 0.66. ICU Medical, Inc. has a 52 week low of $82.82 and a 52 week high of $196.26. The business has a 50 day simple moving average of $176.59 and a 200 day simple moving average of $144.30.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.